Novo Nordisk (NVO) receives EC approval for its fast-acting insulin aspart, Fiasp, for the treatment of diabetes in adolescents and children aged one year or older.
source https://finance.yahoo.com/news/novo-nordisks-fiasp-gets-ec-183706660.html?.tsrc=rss
blaineonline.finance.blog 